UBS cuts CME Group price target to $285 from $305

UBS cuts CME Group price target to $285 from $305

September 02, 2025

In a recent development, UBS has revised its price target for CME Group Inc. (NASDAQ:CME) from $305 to $285, while maintaining a Neutral rating [1]. This adjustment comes amidst a series of positive earnings and ownership developments for the company.

CME Group reported a strong earnings per share (EPS) of $2.96 for the quarter, surpassing the consensus estimate of $2.91. Additionally, the company experienced a year-over-year revenue increase of 10.4%. These positive financial metrics, coupled with increased institutional ownership, have contributed to the upward trend in the stock's price.

Several institutional investors, including GQG Partners and Wellington Management Group, have significantly increased their stakes in CME Group during the first quarter. Amundi, for instance, sold 576,014 shares, reducing its position by 26.4%, while GQG Partners increased its stake by 7,676.3%, now owning 2,205,041 shares. Other notable increases include Wellington Management Group (370.5%) and GAMMA Investing LLC (32,941.0%) [2].

Despite the positive developments, UBS's lower price target suggests a cautious stance on the company's future prospects. The investment bank may be factoring in potential risks or market volatility that could impact CME Group's performance. However, UBS maintains a Neutral rating, indicating a balanced view of the company's prospects.

Institutional ownership of CME Group remains notably high at 87.75%, with several investors significantly increasing their stakes. Focus Partners Advisor Solutions LLC, for instance, increased its position by 156.3% in the first quarter [3]. Several other hedge funds have also boosted their stakes in CME Group, with Vanguard Group increasing its holdings by 1.2% and Wellington Management Group raising its position by 370.5% [4].

The company has also seen a series of positive analyst ratings and price targets. Piper Sandler boosted its price objective to $296, while Barclays set a target of $298.00. Despite these positive developments, UBS's lower price target suggests a cautious approach to the company's future prospects.

References:
[1] https://www.ainvest.com/news/cme-group-ubs-lowers-pt-285-maintains-neutral-rating-2509/
[2] https://www.marketbeat.com/instant-alerts/filing-amundi-sells-576014-shares-of-cme-group-inc-cme-2025-09-04/
[3] https://www.marketbeat.com/instant-alerts/filing-focus-partners-advisor-solutions-llc-increases-position-in-cme-group-inc-cme-2025-09-04/
[4] https://www.marketbeat.com/instant-alerts/filing-focus-partners-advisor-solutions-llc-increases-position-in-cme-group-inc-cme-2025-09-04/